Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial
Introduction Despite the improvement in medical management, many patients with transfusion-dependent β-thalassaemia die prematurely due to transfusion-related iron overload. As per the current guidelines, the optimal chelation of iron cannot be achieved in many patients, even with two iron chelators...
Main Authors: | Anuja Premawardhena, Sachith Mettananda, Chamodi Perera, Muditha Nayana Wijethilaka, Sakuni Keshani Wanasinghe, R H M G Rajakaruna, R A N K K Samarasinghe, Senani Williams |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-02-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/14/2/e077342.full |
Similar Items
-
Deferasirox effectively removes cardiac iron in beta-thalassaemia patients with myocardial siderosis previously chelated with deferoxamine monotherapy or deferoxamine-deferiprone therapy
by: Pennell, D., et al.
Published: (2010) -
Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
by: Wu D, et al.
Published: (2018-05-01) -
Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload
by: Gotsis Efstathios D, et al.
Published: (2011-07-01) -
Comparison of the Mean Serum Ferritin Levels in Thalassaemia Major Patients after Giving Deferasirox and Deferoxamine
by: Seema Aftab, et al.
Published: (2017-12-01) -
Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
by: Sujian Xia, et al.
Published: (2013-01-01)